Weight-loss drugs such as Ozempic, Mounjaro, Wegovy, and Zepbound are revolutionizing the field of obesity treatment, with significant economic implications. These medications, developed by companies like Novo Nordisk and Eli Lilly, are not only aiding in weight loss but also showing potential in reducing heart disease risk, treating sleep apnea, and addressing other health issues. Despite their benefits, there are concerns about long-term effects and the potential for shortages due to high demand. Eli Lilly's Zepbound is seeing more patients paying the full list price compared to its predecessor Mounjaro. Additionally, Eli Lilly expects data from its late-stage trial on the experimental obesity pill orforglipron in April 2025. Female patients accounted for at least 78% of total prescriptions for Wegovy and 76% or more total prescriptions for Zepbound between January and March. Meanwhile, a new obesity-drug startup has emerged with $290 million in funding, aiming to compete with established drugs like Wegovy and Zepbound.
A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro. https://t.co/9Yj3Dk0Xr1 https://t.co/9Yj3Dk0Xr1
With everyone from obesity patients to celebrities demanding Ozempic and other drugs like it, the frenzy has sparked global shortages—opening the door to life-threatening fakes. https://t.co/Rd1wbeo5SB
Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program https://t.co/zCahQMSdqS
Eli Lilly exec expects obesity pill data in April 2025 https://t.co/rCmYeabtRM https://t.co/g05zOFuHgO
Eli Lilly exec says seeing out of pocket payments for obesity drug in US https://t.co/GfkfXNQ37V https://t.co/Bkdw0uOxOH
$PFE should be reporting data from their once daily GLP-1 drug Danuglipron soon likely around mid year. I believe their once daily drug will disappoint as a competitive threat in the oral drug arena compared to $VKTX and or $GPCR though $GPCR has it's own safety issues ⬇️⬇️
📍The future of GLP-1 medicines encompasses a multiagonist approach #obesity https://t.co/4hIcOQwP7T
Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday. https://t.co/AUzQhDRr6P https://t.co/AUzQhDRr6P
A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro. https://t.co/7lWP2AsahB https://t.co/7lWP2AsahB
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan' https://t.co/dP7OzZY7Z5 by @AnjKhem
This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound https://t.co/HbyVVBP5Fy
"Female patients accounted for at least 78% of total prescriptions for Wegovy and 76% or more total prescriptions for Zepbound between January and March." https://t.co/QiAI5vF5Cp
Focus: Added health benefits of Wegovy, Zepbound could attract more men, doctors say https://t.co/1TSsJfJODT https://t.co/1TSsJfJODT
🔵 ADDED HEALTH BENEFITS OF WEGOVY, ZEPBOUND COULD ATTRACT MORE MEN, DOCTORS SAY Full Story → https://t.co/mapjDoDmy2 Evidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart disease risk, treat sleep apnea and address other health… https://t.co/DzOoTLiTW6
New drugs could spell an end to the world’s obesity epidemic. The long-term effects must be carefully studied—but the excitement is justified https://t.co/AVinrA038e👇
Drugs like Ozempic and Mounjaro are revolutionizing weight loss, but will they also revolutionize the economy? @_jessicamendoza and @bradnews answer questions on how this class of drugs is transforming bodies, fortunes and industries. Listen 🎧: https://t.co/Q3CW5m7pYj